{"id":33362,"date":"2025-05-14T12:04:58","date_gmt":"2025-05-14T04:04:58","guid":{"rendered":"https:\/\/flcube.com\/?p=33362"},"modified":"2025-05-14T12:04:59","modified_gmt":"2025-05-14T04:04:59","slug":"legend-biotechs-q1-2025-results-highlight-carvykti-sales-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33362","title":{"rendered":"Legend Biotech&#8217;s Q1 2025 Results Highlight Carvykti Sales Growth"},"content":{"rendered":"\n<p>China-based Legend Biotech Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/LEGN:NASDAQ\">NASDAQ: LEGN<\/a>) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.<\/p>\n\n\n\n<p><strong>Financial Highlights<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>License Revenue<\/strong>: USD 9.3 million, a decrease from USD 12.2 million in the same period last year. This decline is attributed to revenue recognized under the license agreement with Novartis for LB2102 and other DLL-3 targeted CAR-T therapies. Revenue is recognized over time as Legend Biotech conducts a Phase I clinical trial for LB2102.<\/li>\n\n\n\n<li><strong>Collaboration Revenue<\/strong>: USD 185.6 million, up from USD 78.5 million in the first quarter of 2024. This increase is primarily due to higher revenue generated from Carvykti sales under the collaboration and license agreement with Janssen.<\/li>\n\n\n\n<li><strong>Net Loss<\/strong>: USD 100.9 million.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Legend-Biotech-Reports-First-Quarter-2025-Results-and-Recent-Highlights.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Legend Biotech Reports First Quarter 2025 Results and Recent Highlights.\"><\/object><a id=\"wp-block-file--media-6403686c-71c3-4efd-964e-f4287307fb1b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Legend-Biotech-Reports-First-Quarter-2025-Results-and-Recent-Highlights.pdf\">Legend Biotech Reports First Quarter 2025 Results and Recent Highlights<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Legend-Biotech-Reports-First-Quarter-2025-Results-and-Recent-Highlights.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6403686c-71c3-4efd-964e-f4287307fb1b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33370,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,112,873],"class_list":["post-33362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-legend-biotech","tag-nasdaq-legn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Legend Biotech&#039;s Q1 2025 Results Highlight Carvykti Sales Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33362\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legend Biotech&#039;s Q1 2025 Results Highlight Carvykti Sales Growth\" \/>\n<meta property=\"og:description\" content=\"China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33362\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T04:04:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-14T04:04:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Legend Biotech&#8217;s Q1 2025 Results Highlight Carvykti Sales Growth\",\"datePublished\":\"2025-05-14T04:04:58+00:00\",\"dateModified\":\"2025-05-14T04:04:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362\"},\"wordCount\":155,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1405.webp\",\"keywords\":[\"Finanical Reports\",\"Legend Biotech\",\"NASDAQ: LEGN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33362#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33362\",\"name\":\"Legend Biotech's Q1 2025 Results Highlight Carvykti Sales Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1405.webp\",\"datePublished\":\"2025-05-14T04:04:58+00:00\",\"dateModified\":\"2025-05-14T04:04:59+00:00\",\"description\":\"China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33362\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Legend Biotech's Q1 2025 Results Highlight Carvykti Sales Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33362#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legend Biotech&#8217;s Q1 2025 Results Highlight Carvykti Sales Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Legend Biotech's Q1 2025 Results Highlight Carvykti Sales Growth - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33362","og_locale":"en_US","og_type":"article","og_title":"Legend Biotech's Q1 2025 Results Highlight Carvykti Sales Growth","og_description":"China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.","og_url":"https:\/\/flcube.com\/?p=33362","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-14T04:04:58+00:00","article_modified_time":"2025-05-14T04:04:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33362#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33362"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Legend Biotech&#8217;s Q1 2025 Results Highlight Carvykti Sales Growth","datePublished":"2025-05-14T04:04:58+00:00","dateModified":"2025-05-14T04:04:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33362"},"wordCount":155,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33362#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp","keywords":["Finanical Reports","Legend Biotech","NASDAQ: LEGN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33362#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33362","url":"https:\/\/flcube.com\/?p=33362","name":"Legend Biotech's Q1 2025 Results Highlight Carvykti Sales Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33362#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33362#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp","datePublished":"2025-05-14T04:04:58+00:00","dateModified":"2025-05-14T04:04:59+00:00","description":"China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue contributions from its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The therapy generated net sales of USD 369 million during the quarter and has treated over 6,000 patients to date.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33362#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33362"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33362#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp","width":1080,"height":608,"caption":"Legend Biotech's Q1 2025 Results Highlight Carvykti Sales Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33362#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Legend Biotech&#8217;s Q1 2025 Results Highlight Carvykti Sales Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33362"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33362\/revisions"}],"predecessor-version":[{"id":33371,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33362\/revisions\/33371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33370"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}